Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.6c00746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Marian N Aziz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, Texas75390, United States. Hauptthemen laut MEDLINE: Nectins, Zirconium, Urinary Bladder Neoplasms, Radioisotopes. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Cancer Prevention and Research Institute of Texas, University of Texas Southwestern Medical Center.
Abstract (Originalsprache)
Nectin-4–targeted imaging has emerged as a promising strategy for patient stratification in urothelial carcinoma, yet currently available radiotracers remain limited by rapid renal clearance, urinary background activity, or potential pharmacologic confounding associated with antibody-drug conjugate (ADC)-based constructs. To overcome some of these limitations, we developed a payload-free immunoPET radiotracer based on the native enfortumab antibody conjugated with the bifunctional chelator DFO*-sq and radiolabeled with zirconium-89 (89Zr). The resulting [89Zr]Zr-DFO*-sq-Enfortumab preserved Nectin-4–specific targeting while demonstrating high radiochemical stability in human serum (>99% through Day 12). In vitro studies showed efficient antigen-specific cellular internalization (80–85%), prolonged intracellular retention, and evidence consistent with partial recycling of antibody-associated species. In vivo, [89Zr]Zr-DFO*-sq-Enfortumab exhibited sustained tumor uptake reaching 17.4 ± 2.8% ID/g in high Nectin-4–expressing xenografts and correlated with differential Nectin-4 expression across multiple bladder cancer models. Importantly, the full-length antibody platform enabled high-contrast visualization of pulmonary metastatic lesions and orthotopic bladder tumors despite some urinary background activity. Together, these findings demonstrate that payload-free [89Zr]Zr-DFO*-sq-Enfortumab provides a biologically relevant immunoPET platform for noninvasive assessment of variable Nectin-4 expression and support its further evaluation as a companion imaging strategy for Enfortumab Vedotin–based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, Texas75390, United States.
- Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas75390United States.
- Lyda Hill Department of Bioinformatics, The University of Texas Southwestern Medical Center, Dallas, Texas75390, United States.
- The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas77030, United States.
- Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, Dallas, Texas75390, United States.
- Department of Internal Medicine, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas75390, United States.
ORCID-Profile: Xiankai Sun
Förderung
- Cancer Prevention and Research Institute of Texas
- University of Texas Southwestern Medical Center
Zitieren
APA
Aziz, M. N., Wang, T., Lang, J., Glover, M., Boppana, A., Debnath, S., Loh, J. W., Lee, J., Yan, S., Zhang, N., Sun, X., Hsieh, J. T., Wang, J., Liu, L., & Hao, G. (2026). Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00746
Vancouver
Aziz MN, Wang T, Lang J, Glover M, Boppana A, Debnath S, et al. Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00746
BibTeX
@article{Aziz2026,
author = {Aziz, Marian N and Wang, Tianyuan and Lang, Jiawen and Glover, Mickey and Boppana, Abhilash and Debnath, Sashi and Loh, Jui Wan and Lee, Jeon and Yan, Sean and Zhang, Ningyan and Sun, Xiankai and Hsieh, Jer-Tsong and Wang, Jue and Liu, Li and Hao, Guiyang},
title = {Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00746}
}
EUVIMED